Welcome to our dedicated page for Revance Therapeu news (Ticker: RVNC), a resource for investors and traders seeking the latest updates and insights on Revance Therapeu stock.
The RVNC news page on Stock Titan provides an archive of announcements and transaction-related communications concerning Revance Therapeutics, Inc., a biotechnology company focused on aesthetic and therapeutic offerings. These news items document Revance’s role in the aesthetic injectables market, its product portfolio, and the corporate events that led to its acquisition by Crown Laboratories, Inc.
Readers can review press releases describing Crown’s commencement of a cash tender offer to acquire all outstanding shares of Revance, subsequent extensions of the tender offer, and an increase in the offer price that was unanimously approved by the Revance Board of Directors. Additional news items cover competing interest from Teoxane SA, reminders to Revance stockholders about tendering their shares, and joint announcements by Crown and Revance regarding the expiration of the tender offer and satisfaction of its conditions.
The archive also includes Crown’s announcements of the successful closing of the acquisition and completion of the second-step merger, in which Crown stated that Revance’s common stock will be delisted from the NASDAQ Global Select Market and deregistered. These releases provide context on how Revance, as the issuer of RVNC, transitioned from an independent publicly traded biotechnology company to a Crown-owned business within a larger skincare and aesthetics platform.
For investors and researchers, the RVNC news feed serves as a historical record of key milestones, including strategic reviews by the Revance Board, tender offer mechanics, and the ultimate outcome of the Crown transaction. Users interested in the evolution of Revance’s aesthetic and therapeutic portfolio, its partnerships with Teoxane SA, Viatris Inc., and Shanghai Fosun Pharmaceutical, and the terms of the acquisition can use this page to trace the sequence of public communications around the deal.
Summary not available.
Summary not available.
Summary not available.
Revance Therapeutics, Inc. (NASDAQ: RVNC) will participate in the 22nd Annual Needham Virtual Healthcare Conference from April 17-20, 2023. CFO Tobin Schilke is set to engage in a fireside chat on April 18 at 12:45 PM ET. The conference's live audio webcast can be accessed via the company's Investor Relations page, with a replay available for 90 days post-event. Revance focuses on innovative aesthetic and therapeutic solutions, including the DAXXIFY® injection for muscle movement disorders. Headquartered in Nashville, Tennessee, Revance also operates in Newark, Pleasanton, and Irvine, California.
Summary not available.
Revance Therapeutics, Inc. (RVNC) announced its participation in upcoming investor conferences. CEO Mark J. Foley will engage in a fireside chat at the Barclays Global Healthcare Conference on
Revance specializes in innovative aesthetic and therapeutic solutions, including DAXXIFY® and the RHA® Collection, enhancing patient and physician experiences.
The facial injectable market was valued at
Revance Therapeutics, Inc. (RVNC) reported Q4 2022 total revenue of $49.9 million, a 92% year-over-year increase, while full-year revenue reached $132.6 million, up 70%. The RHA® Collection drove $34.8 million in quarterly revenue, and DAXXIFY® generated $11.0 million during its PrevU program. Despite revenue growth, operating expenses surged to $194.3 million for Q4, impacted by a $69.8 million goodwill impairment. The company anticipates 2023 operating expenses of $460 million to $480 million. DAXXIFY® is set to launch commercially in late March 2023, with a PDUFA date for cervical dystonia on August 19, 2023.
Revance Therapeutics (RVNC) appointed Dr. Vlad Coric to its Board of Directors, effective March 1, 2023. Dr. Coric, with over 22 years of experience in drug development, previously served as Chairman and CEO of Biohaven. He is credited with the successful commercialization of Nurtec® ODT and played a key role in Biohaven's acquisition by Pfizer for $13 billion. Revance's CEO, Mark J. Foley, highlighted Dr. Coric's expertise as beneficial during a pivotal time for the company, focusing on both aesthetic and therapeutic growth, particularly with DAXXIFY®. Additionally, Dr. Philip Vickers is retiring from the Board ahead of the annual meeting.
Revance Therapeutics, Inc. (RVNC) will participate in the 43rd Annual Cowen Healthcare Conference from March 6-8, 2023, in Boston, Massachusetts. CEO Dustin S. Sjuts and CFO Tobin Schilke will engage in a fireside chat on Monday, March 6 at 9:50 A.M. EST. Interested viewers can access the live audio webcast through the Investor Relations section of their website, with a replay available for 90 days post-event. Revance focuses on developing innovative aesthetic and therapeutic solutions, including DAXXIFY® and a biosimilar to onabotulinumtoxinA, targeting muscle movement disorders.